Literature DB >> 11455857

Combination treatment in autoimmune diseases. Methodology of combination trials.

M Boers1.   

Abstract

Even with the limited number of antirheumatic agents available, theoretical considerations lead to an almost infinite number of combination strategies. This article outlines possible strategies based on the primary choice between maximization of efficacy or minimization of toxicity. Strategies are illustrated with examples from trial experience in the field of rheumatoid arthritis.

Entities:  

Mesh：

Substances：

Year:  2001        PMID： 11455857     DOI： 10.1007/s002810100073

Source DB:  PubMed          Journal:  Springer Semin Immunopathol        ISSN： 0344-4325


  10 in total

Review 1.  Combination therapy for autoimmune diseases: the rheumatoid arthritis model.

Authors:  N Fathy; D E Furst
Journal:  Springer Semin Immunopathol       Date:  2001

2.  Comparison of combination therapy with single-drug therapy in early rheumatoid arthritis: a randomised trial. FIN-RACo trial group.

Authors:  T Möttönen; P Hannonen; M Leirisalo-Repo; M Nissilä; H Kautiainen; M Korpela; L Laasonen; H Julkunen; R Luukkainen; K Vuori; L Paimela; H Blåfield; M Hakala; K Ilva; U Yli-Kerttula; K Puolakka; P Järvinen; M Hakola; H Piirainen; J Ahonen; I Pälvimäki; S Forsberg; K Koota; C Friman
Journal:  Lancet       Date:  1999-05-08       Impact factor: 79.321

3.  Randomised comparison of combined step-down prednisolone, methotrexate and sulphasalazine with sulphasalazine alone in early rheumatoid arthritis.

Authors:  M Boers; A C Verhoeven; H M Markusse; M A van de Laar; R Westhovens; J C van Denderen; D van Zeben; B A Dijkmans; A J Peeters; P Jacobs; H R van den Brink; H J Schouten; D M van der Heijde; A Boonen; S van der Linden
Journal:  Lancet       Date:  1997-08-02       Impact factor: 79.321

4.  Remodeling the pyramid--a concept whose time has come.

Authors:  K R Wilske; L A Healey
Journal:  J Rheumatol       Date:  1989-05       Impact factor: 4.666

5.  The efficacy and toxicity of combination therapy in rheumatoid arthritis. A meta-analysis.

Authors:  D T Felson; J J Anderson; R F Meenan
Journal:  Arthritis Rheum       Date:  1994-10

6.  Combination therapy in early rheumatoid arthritis: a randomised, controlled, double blind 52 week clinical trial of sulphasalazine and methotrexate compared with the single components.

Authors:  M Dougados; B Combe; A Cantagrel; P Goupille; P Olive; M Schattenkirchner; S Meusser; L Paimela; R Rau; H Zeidler; M Leirisalo-Repo; K Peldan
Journal:  Ann Rheum Dis       Date:  1999-04       Impact factor: 19.103

7.  Comparison of auranofin, methotrexate, and the combination of both in the treatment of rheumatoid arthritis. A controlled clinical trial.

Authors:  H J Williams; J R Ward; J C Reading; R H Brooks; D O Clegg; J L Skosey; M H Weisman; R F Willkens; J Z Singer; G S Alarcón
Journal:  Arthritis Rheum       Date:  1992-03

Review 8.  Combination therapy in rheumatoid arthritis: updated systematic review.

Authors:  A C Verhoeven; M Boers; P Tugwell
Journal:  Br J Rheumatol       Date:  1998-06

9.  Oral steroids as bridge therapy in rheumatoid arthritis patients starting with parenteral gold. A randomized double-blind placebo-controlled trial.

Authors:  A M van Gestel; R F Laan; C J Haagsma; L B van de Putte; P L van Riel
Journal:  Br J Rheumatol       Date:  1995-04

10.  Combination therapy with gold and hydroxychloroquine in rheumatoid arthritis: a prospective, randomized, placebo-controlled study.

Authors:  D L Scott; P T Dawes; E Tunn; P D Fowler; M F Shadforth; J Fisher; S Clarke; M Collins; P Jones; A J Popert
Journal:  Br J Rheumatol       Date:  1989-04
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.